MedPath

33-104 : Drug Use-Results Survey of OPDIVO

Not Applicable
Conditions
nresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chem
Registration Number
JPRN-jRCT2011230029
Lead Sponsor
Kuro Toshihiko
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time

Exclusion Criteria

Patients who have received OPDIVO previously

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
[Safety]<br>a) Occurrence status of adverse drug reactions and infections, <br>b) Factors that are considered to affect safety<br>c) Adverse events
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath